NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

對KOL的考慮:《黑色素瘤2020》

KOL Insight: Melanoma 2020

出版商 FirstWord 商品編碼 995057
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
對KOL的考慮:《黑色素瘤2020》 KOL Insight: Melanoma 2020
出版日期: 2020年10月13日內容資訊: 英文
簡介

本報告提供了美國和歐洲KOL對黑色素瘤的非處方藥和管線治療前景的評估。

目錄

執行摘要

處理算法

調查目的

非處方藥

  • 概述
  • 免疫療法
    • 重要注意事項摘要
    • Yervoy(ipilimumab; Bristol Myers Squibb)
    • Opdivo(nivolumab; Bristol Myers Squibb/Ono Pharmaceutical)
    • Keytruda(pembrolizumab; Merck&Co.)

BRAF/MEK抑製劑

  • 概述
    • 重要注意事項摘要
  • 非處方BRAF/MEK藥物
    • Tafinlar/Mekinist(dabrafenib/trametinib; Novartis) Zelboraf/Cotellic(vemurafenib/cobimetinib; Roche) Braftovi/Mektovi(encorafenib/binimetinib; Array Biopharma)

溶瘤病毒/免疫刺激劑

  • 概述
    • Imlygic(talimogene laherparepvec; Amgen)

管道補救措施

  • 概述

CTLA4/PD-1/PDL-1/LAG-3抑製劑

  • 概述
    • 重要注意事項摘要
    • 關鍵見解摘要 IBI310(ipilimumab生物仿製藥; Innovent Biologics) Relatlimab(百時美施貴寶(Bristol Myers Squibb)/小野製藥(Ono Pharmaceuticals)) 斯巴達珠單抗(PDR001;諾華) Tyvyt(sintilimab; Innovent Biologics/禮來

Toll樣受體9(TLR9)激動劑

  • 概述
    • 重要注意事項摘要
    • 替洛索莫特(Idera Pharmaceuticals)

VEGFR/FGFR/PDGFR/RTK抑製劑

  • 概述
    • 重要注意事項摘要
    • Lenvima(lenvatinib; Eisai/Merck&Co.)

重組免疫刺激劑

  • 概述
    • 重要注意事項摘要
    • Bempegal desleukin(Nektar/BMS)
    • Seviprotimut-L(POL 103A; Polynoma)

早期管線藥物

  • 概述
    • 重要注意事項摘要
    • ATG-019 (KPT-9274; Karyopharm Therapeutics)
    • BI-1206 (BioInvent International)
    • BNT111 (BioNTech)
    • Ceralasertib (AstraZeneca)
    • Inlyta (axitinib; Pfizer)
    • IO102 (IO Biotech)
    • LN-144 (lifileucel; Iovance Biotherapeutics)
    • Tebentafusp (Immunocore)

附錄

新聞

目錄

Must-Know Insights From The World's Foremost Thought-Leaders

Answer critical business questions with deep intelligence from those already in-the-know

Why do KOLs foresee an expansion of Merck's anti-PD-1 therapy Keytruda in the adjuvant setting? Could Eli Lilly/Innovent Biologics' sintilimab/ipilimumab biosimilar combination threaten BMS' Opdivo/Yervoy domination of advanced melanoma treatment? <>And why do KOLs believe Iovance Biotherapeutics' pipeline lifileucel has the potential to change practice for patients' refractory to multiple-lines of therapy? US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.

Key questions answered:

  • Why do oncologists suggest the anti-PD1/CTLA4 blockade could be practice changing in the neoadjuvant setting?
  • Why are experts underwhelmed with Roche's triple combination of Tecentriq with Cotellic/Zelboraf?
  • Why do KOLs believe Nektar/BMS' late stage bempegaldesleukin/nivolumab combination could be a potential competitor to Opdivo/Yervoy?
  • How and where do oncologists see potential value for Idera's PIII tilsotolimod/Yervoy combination?

Examples of Therapies Covered:

  • Yervoy
  • Keytruda
  • Tafinlar/Mekinist
  • Relatlimab
  • Tilsotolimod
  • Opdivo
  • IBI310
  • Zelboraf/Cotellic
  • Spartalizumab
  • Tyvyt

Partial List of Participating KOLs:

  • Oncology Specialist, MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC.
  • Professor of Medicine (Hematology/Oncology), Roswell Park Cancer Institute, 915 CSC Building, Elm and Carlton Streets, Buffalo, NY.
  • Oncology Specialist, Professor, Moffitt Cancer Center and University of South Florida Morsani College of Medicine, Tampa, FL.
  • Professor & Chief Scientific Officer, Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands.
  • Professor of Medicine, Head of the Dermatology Unit at the Gustave Roussy Cancer Centre, Villejuif-Paris, France.
  • Professor of Medicine, University of Zurich, Vice-Chairman, Department of Dermatology, University Hospital of Zürich. Switzerland.

Table of Contents

Executive summary

Treatment algorithm

Research objectives

Marketed therapies

  • Overview
  • Immunotherapies
    • Key insights summary
    • Yervoy (ipilimumab; Bristol Myers Squibb)
    • Opdivo (nivolumab; Bristol Myers Squibb/Ono Pharmaceutical)
    • Keytruda (pembrolizumab; Merck & Co.)

BRAF/MEK inhibitors

  • Overview
    • Key insights summary
  • Marketed BRAF/MEK drugs
    • Tafinlar/Mekinist (dabrafenib/trametinib; Novartis)
    • Zelboraf/Cotellic (vemurafenib/cobimetinib; Roche)
    • Braftovi/Mektovi (encorafenib/binimetinib; Array Biopharma)

Oncolytic viruses/immunostimulants

  • Overview
    • Imlygic (talimogene laherparepvec; Amgen)

Pipeline therapies

  • Overview

CTLA4/PD-1/PDL-1/LAG-3 inhibitors

  • Overview
    • Key insights summary
    • IBI310 (ipilimumab biosimilar; Innovent Biologics)
    • Relatlimab (Bristol Myers Squibb/Ono Pharmaceuticals)
    • Spartalizumab (PDR001; Novartis)
    • Tyvyt (sintilimab; Innovent Biologics/Lilly

Toll-like receptor 9 (TLR9) agonists

  • Overview
    • Key insights summary
    • Tilsotolimod (Idera Pharmaceuticals)

VEGFR/FGFR/PDGFR/RTK inhibitors

  • Overview
    • Key insights summary
    • Lenvima (lenvatinib; Eisai/Merck & Co.)

Recombinant immunostimulants

  • Overview
    • Key insights summary
    • Bempegaldesleukin (Nektar/BMS)
    • Seviprotimut-L (POL 103A; Polynoma)

Early-stage pipeline drugs

  • Overview
    • Key insights summary
    • ATG-019 (KPT-9274; Karyopharm Therapeutics)
    • BI-1206 (BioInvent International)
    • BNT111 (BioNTech)
    • Ceralasertib (AstraZeneca)
    • Inlyta (axitinib; Pfizer)
    • IO102 (IO Biotech)
    • LN-144 (lifileucel; Iovance Biotherapeutics)
    • Tebentafusp (Immunocore)

Appendix

  • KOL details
    • KOLs from North America
    • KOLs from Europe

News